Published in Blood on July 22, 2008
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost (2012) 2.09
Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood (2011) 1.73
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood (2012) 1.57
FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood (2014) 1.50
Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.46
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite. Blood (2009) 1.02
Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler Thromb Vasc Biol (2011) 0.89
Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood (2011) 0.86
Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost (2013) 0.83
Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment. Blood (2014) 0.81
Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost (2014) 0.79
The regulation of factor IXa by supersulfated low molecular weight heparin. Biochemistry (2010) 0.78
A mouse bleeding model to study oral anticoagulants. Thromb Res (2014) 0.77
Swine Model of Thrombotic Caval Occlusion Created by Autologous Thrombus Injection with Assistance of Intra-caval Net Knitting. Sci Rep (2015) 0.75
Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Ther (2016) 0.75
Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice. J Thromb Haemost (2016) 0.75
Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta (1991) 5.09
Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb (2003) 4.44
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry (1986) 2.77
A coagulation factor IX-deficient mouse model for human hemophilia B. Blood (1997) 2.36
Blood clotting in minimally altered whole blood. Blood (1996) 2.10
The tertiary structure and domain organization of coagulation factor VIII. Blood (2007) 1.96
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost (2005) 1.92
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA (2006) 1.72
A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem (1994) 1.53
Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost (2006) 1.49
Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A (1988) 1.35
The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost (2005) 1.35
Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem (1996) 1.28
Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem (1998) 1.24
The significance of circulating factor IXa in blood. J Biol Chem (2004) 1.22
Thrombin generation: phenotypic quantitation. J Thromb Haemost (2004) 1.22
Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid. Blood (1984) 1.21
Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost (2004) 1.18
Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem (1994) 1.07
The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem (1998) 1.07
Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism. Blood (2006) 1.03
Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem (1992) 1.01
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood (1995) 0.98
Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry (2004) 0.94
The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry (2005) 0.90
The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X. Biochemistry (2007) 0.89
The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity. J Biol Chem (1999) 0.82
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica (2008) 1.67
Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg (2013) 1.43
Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite. Blood (2009) 1.02
Activation of factor XI by products of prothrombin activation. Blood (2011) 0.99
RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett (2004) 0.93
Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem (2010) 0.92
The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry (2005) 0.90
Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler Thromb Vasc Biol (2011) 0.89
The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X. Biochemistry (2007) 0.89
Blood utilization in patients with burn injury and association with clinical outcomes (CME). Transfusion (2012) 0.83
Molecular mapping of the thrombin-heparin cofactor II complex. J Biol Chem (2004) 0.80
The regulation of factor IXa by supersulfated low molecular weight heparin. Biochemistry (2010) 0.78
Serpins (serine protease inhibitors). Curr Protoc Protein Sci (2002) 0.78
Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin. Am J Cardiol (2004) 0.78
Substitution of a heparin correlation value for activated partial thromboplastin time in heparin nomograms. Am J Health Syst Pharm (2011) 0.75
Interferon-α is not elevated in idiopathic thrombotic thrombocytopenic purpura patients. J Clin Apher (2014) 0.75
Transfusion medicine illustrated. Hemoglobin D after a red-cell exchange for sickle-cell disease. Transfusion (2008) 0.75